GlobeNewsWire
01 Jun 2026, 06:00 UTC · 3h ago
Source · https://www.globenewswire.com/news-release/2026/06/01/3304013/0/en/Avacta-presents-updated-clinical-data-showing-encouraging-early-efficacy-signals-for-AVA6000-in-salivary-gland-cancers-at-ASCO-2026.html
Read source
Search tags
Story key points
3 claims · impact-rated
Avacta's AVA6000 demonstrated a 92% disease control rate in salivary gland cancer (SGC) patients, including multiple confirmed partial and minor responses. — Strong preliminary efficacy data in a specific cancer cohort increases the probability of success for future late-stage trials and regulatory approval.
+0.70The company removed the lifetime maximum doxorubicin limit for AVA6000 after data showed no severe cardiac toxicity and no cardiomyopathy events. — Removing a critical dosing limit significantly expands the drug's therapeutic window and utility, addressing a major historical limitation of doxorubicin.
+0.60AVA6000 was administered at a dose nearly three times the maximum tolerated dose of conventional doxorubicin while maintaining lower toxicity rates. — Evidence of superior safety at higher doses validates the pre|CISION platform's ability to deliver payloads more effectively than standard chemotherapy.
+0.50Ticker attribution
Continue reading
6 related stories
Model heads
The company reported encouraging clinical efficacy data and a favorable safety profile for its AVA6000 oncology drug.
No ticker relationship head found.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
GlobeNewsWire
1d ago
